What is Clene Nanomedicine?
Clene Nanomedicine is a clinical-stage pharmaceutical innovator dedicated to the discovery and development of clean-surfaced nanotechnology (CSN) therapeutics. The company's flagship candidate, CNM-Au8, is currently undergoing rigorous evaluation across multiple Phase 2 clinical trials, targeting complex conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. Beyond its neurological focus, the company is expanding its reach into infectious disease management with agents like CNM-AgZn17 and CNM-ZnAg, which utilize silver and zinc ion technology to support wound healing and immune response. By integrating advanced material science with pharmaceutical rigor, Clene Nanomedicine is redefining the therapeutic potential of nanotechnology in modern medicine.
How much funding has Clene Nanomedicine raised?
Clene Nanomedicine has raised a total of $140.3M across 7 funding rounds:
Series A
$31.6M
Series B
$17M
Debt
$350K
Series D
$42.5M
Other Financing Round
$40M
Other Financing Round
$7.3M
Stock/Share Issuance
$1.5M
Series A (2015): $31.6M, investors not publicly disclosed
Series B (2016): $17M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $42.5M featuring SymBiosis II
Other Financing Round (2023): $40M backed by Vivo Capital, Acuta Capital Partners, and Symbiosis Group
Other Financing Round (2024): $7.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Key Investors in Clene Nanomedicine
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996 that specializes in private and public equity as well as venture capital for the life sciences sector.
Acuta Capital Partners
Acuta Capital Partners is a California-based investment group focused on healthcare innovation and supporting companies that aim to improve patient health outcomes.
Symbiosis Group
Symbiosis Group is an academic and scholarly publishing entity that provides open access journals and high-impact research resources to the scientific community.
What's next for Clene Nanomedicine?
With the recent influx of capital, Clene Nanomedicine is well-positioned to advance its clinical trial programs and refine its manufacturing processes for its CSN-based therapeutics. The strategic focus will likely remain on completing ongoing Phase 2 studies and preparing for potential late-stage clinical evaluations. As the company navigates the complexities of the pharmaceutical regulatory environment, the continued support from institutional investors will be instrumental in scaling operations and exploring new therapeutic applications for its nanotechnology platform. The firm's ability to maintain a robust pipeline while securing consistent funding highlights its resilience and long-term potential in the competitive biotechnology sector.
See full Clene Nanomedicine company page
